Biohaven (BHVN) Stock Plummets After Pausing Midstage Seizure Treatment Study Due to Safety Concerns and FDA Toxicity Assessment Requirement
Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment opakalim due to safety concerns. The Food and Drug Administration (FDA) is now requiring Biohaven to assess the potential for human toxicity from a metabolite in the drug, which is in testing for focal onset seizures, after issues were observed in rats.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
The bank raised its 2027 humanoid robot sales forecast for Unitree Robotics to 31,701 units
-
2
Meta's earnings triggered a significant widening of AI credit spreads, with its Credit Default Swaps (CDS) reaching an all-time high
-
3
What is NBM Coin (NFTBlackmarket)? Status and Trading Channels Analysis
-
4
shows that the computational power consumption for training humanoid robot full-body motion controllers can be compressed by over 1000 times
-
5
AI Tokens Explained: Definition, Key Projects, and Market Outlook for Artificial Intelligence Cryptocurrencies
-
6
Brent crude prices fell below $110/barrel, down over 6% from Friday's high
-
7
Israel will hold general elections on Tuesday, with war, security, the economy, and coalition formation being the main issues
-
8
What is EURe? An Analysis of the Euro Stablecoin EURe's Features, Uses, and Trading Channels
-
9
U.S. WTI crude futures fell 2.19% to $101 per barrel, while Brent crude futures dropped 1.89% to $114.51 per barrel
-
10
Virtual Currency Exchange Review: Compliance and Risk Boundaries of Major Global Platforms
Markets Today
Recommended Reading





